NOVEL CLEAVABLE NUCLEOTIDES FOR DNA SEQUENCING BY SYNTHESIS

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,476,109.00
Award Year:
2012
Program:
SBIR
Phase:
Phase II
Contract:
2R44HG004470-02
Agency Tracking Number:
R44HG004470
Solicitation Year:
2012
Solicitation Topic Code:
NHGRI
Solicitation Number:
PA11-096
Small Business Information
INTELLIGENT BIO-SYSTEMS, INC.
34 Bear Hill Rd., Waltham, MA, -
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
170777770
Principal Investigator:
JERZY OLEJNIK
(781) 354-3354
Jerzy@intelligentbiosystems.com
Business Contact:
STEVEN GORDON
(781) 466-8050
sgordon@intelligentbiosystems.com
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): The objective of this proposal is to further optimize Sequencing By Synthesis (SBS) chemistry to power a highly-sensitive, low-cost, sequencing system for clinical diagnostic sequencing called PinPoint MINI. A single human exome at 30 x coverage will be sequenced on this system for less than 150 on an instrument that will sell for under 70,000. The system can run 1-20 samples in parallel generating up to 20 million reads per sample with random sample access in the instrument. Currently, there is no other system on the market which would offer comparable features and performance. The simplicity of the proposed sample preparation and the low cost will enable human exome or targeted sequencing to be widely performed in theclinic and will lead to the revolution in healthcare. This Phase II project has two overall goals: 1) improving sequencing performance (read length and quality) 2) improve sequencing speed. High quality is important to produce more reliable and failsafe genetic diagnostic information and high speed is important to deliver results to physicians and patients quickly. During Phase 2, we will optimize the speed and performance to achieve at least 150 bp read length and reduces our current cycle time to 10 minutes. In addition, we will optimize our novel SBS-walking technology to achieve at least 300 (2 x 150) bp read lengths. Dr. Jeremy Edwards's at the University of New Mexico Health Sciences Center will perform external validation for our sequencing chemistryand systems. PUBLIC HEALTH RELEVANCE: Ultimately, the ability to produce very inexpensive gene expression and detailed DNA sequence information related to cancer will lead for a much wider use of expression and sequence analyses for research and treatment of this devastating disease. In addition, the ability to analyze complex organisms' genomes at a very low cost will both lead to accelerated discoveries throughout biology and provide the basis for Pharmacogenomics, a new paradigm in therapeutics wherein medicines are prescribed based on individual genotypes rather than just observed symptoms.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government